LumiThera Inc., based in Seattle, WA has reported positive results for a “LIGHTSITE II” study, (NCT NCT03878420) conducted by a multi-centre clinical trial in dry… Read More »LumiThera Inc., (Seattle, Washington) announces initial European data on photobiomodulation (PBT) results for treatment of dry AMD
Researchers and the DRCR Retina Network*, funded by the NIH, presented valuable 2-year results for a randomised clinical trial comparing aflibercept treatment vs. sham treatment… Read More »Prophylactic treatment for anti-VEGF for moderate to severe Non-proliferative Diabetic Retinopathy (NPDR) shows an open question – wait or treat?
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2021: “EURETINA-Brief”© Issue No. 233
A report published in Nature Medicine has shown that an RNA antisense oligonucleotide (AON) treatment, directed to the CEP290 gene for LCA10, found one patient… Read More »Leber congenital amaurosis (LCA) reports a sustained improvement for the treatment of a novel anti-oligonucleotide (AON) therapy.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***